|
Medical Advocates Bictegravur |
 |
Main Page New
and NoteworthyJournal DataNews
Releases |
 ARV Investigational
Drugs Main Page |
Drugs Main Page |
Home Page |
Last
Update:
March 23, 2018
 Documents
identified with this icon are in Portable Document Format (PDF) and require the
|
|
New and
Noteworthy |
March 2018
-
Bictegravir: First Global Approval.
Markham A.
|
Journal Papers,
Abstracts, and Commentaries |
-
Bictegravir: First Global Approval.
Markham A.
Drugs. 2018 Mar 21.
Abstract -
Coformulated bictegravir, emtricitabine, and
tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir
alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a
randomised, double-blind, multicentre, phase 3, non-inferiority trial
Sax PE, Pozniak A, Montes ML, et al
Lancet. 2017 Aug 31
Abstract -
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir
alafenamide, for initial treatment of HIV-1 infection: a randomised,
double-blind, phase 2 trial.
Sax PE, DeJesus E, Crofoot G,
et al
-
Antiviral Activity, Safety, and Pharmacokinetics of
Bictegravir as 10-Day Monotherapy in HIV-1-Infected Adults.
Gallant JE, Thompson M, DeJesus E,
-
FULL-TEXT ARTICLE
Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
Tsiang M, Jones GS, Goldsmith J, et al
Antimicrob Agents Chemother. 2016 Nov 21;
Paper
Lancet HIV. 2017 Feb 14.
Abstract
J Acquir Immune Defic Syndr. 2017 Feb 8.
Abstract
|
News
Releases |
|
ARV Investigational
Drugs Main Page |
Drugs Main Page |
Home Page |
|
|